Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial

<h4>Importance</h4> <p>Developing effective vaccines against Ebola virus is a global priority</p> <h4>Objective</h4> <p>To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV) and a modified vaccinia Ankara vector vaccine, e...

Full description

Bibliographic Details
Main Authors:	Milligan, I, Gibani, M, Sewell, R, Clutterbuck, E, Campbell, D, Plested, E, Nuthall, E, Voysey, M, Silva-Reyes, L, McElrath, M, De Rosa, S, Frahm, N, Cohen, K, Shukarev, G, Orzabal, N, van Duijnhoven, W, Truyers, C, Bachmayer, N, Splinter, D, Samy, N, Pau, M, Schuitemaker, H, Luhn, K, Callendret, B, Van Hoof, J, Douoguih, M, Ewer, K, Angus, B, Pollard, A, Snape, M
Format:	Journal article
Language:	English
Published:	American Medical Association 2016

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial

Similar Items